IZO Share Price | Izotropic Corp. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Izotropic Corp. with Similar Stocks

MedX Health Corp.Evome Medical Technologies, Inc.Titan Medical, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 16 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.51

Return on Equity

52.72%

Price to Book

-2.97

Revenue and Profits:

Net Sales:

(Quarterly Results - Jan 2026)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.33%

6 Months

522.22%

1 Year

133.33%

2 Years

-3.45%

3 Years

-47.17%

4 Years

-68.54%

5 Years

80.65%

Izotropic Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

25.84%

EBIT to Interest (avg)

-1.30

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.38

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-2.77

EV to EBIT

-7.14

EV to EBITDA

-7.25

EV to Capital Employed

-6.52

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jan'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jan 2026 is 0.00% vs 0.00% in Jan 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jan 2026 is 40.00% vs -66.67% in Jan 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jan'26",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.30",
          "val2": "-0.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is -93.75% vs 71.93% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-1.60",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "0.40",
          "chgp": "-250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.10",
          "val2": "-1.60",
          "chgp": "-93.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jan'26 - YoY

Jan'26

Jan'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.40

Interest

0.10

Exceptional Items

-0.00

-0.10

100.00%

Consolidate Net Profit

-0.30

-0.50

40.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jan 2026 is 0.00% vs 0.00% in Jan 2025

Consolidated Net Profit

YoY Growth in quarter ended Jan 2026 is 40.00% vs -66.67% in Jan 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Apr'25

Apr'25

Apr'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.20

-1.60

-37.50%

Interest

0.30

Exceptional Items

-0.60

0.40

-250.00%

Consolidate Net Profit

-3.10

-1.60

-93.75%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Consolidated Net Profit

YoY Growth in year ended Apr 2025 is -93.75% vs 71.93% in Apr 2024

All Annual Results

Company CV

About Izotropic Corp.

Izotropic Corp.

Pharmaceuticals & Biotechnology

Izotropic Corporation (Izotropic) is a Canada-based company, which is engaged in commercialization of breast imaging technology for early diagnosis of breast cancer. The Company’s breast computed tomography (CT) imaging system produces breast images in three-dimensional (3D). Izotropic’s imaging system identifies tumors and determines their size, shape, location and depth. The Company makes use of cone-beam computed tomography technology to scan only the breast of interest. Izotropic’s platform computer processes raw images to reconstruct 3D images and allows radiologists to view the breast anatomy from any angle. It also offers a maximum-intensity projection (MIP) viewing capability and zoom capability on a region of interest (ROI).

Company Coordinates

Company Details

15718 39a Ave , SURREY BC : V3Z 0L1

Tel: 1 604 5429458

Registrar Details